Great Point Partners

Jade Biosciences is a biopharmaceutical company dedicated to developing innovative therapies for unmet needs in autoimmune diseases. Its lead asset, JADE-001, targets the APRIL pathway for treating IgA nephropathy, with initial clinical trials planned. Additionally, Jade has two preclinical antibody discovery programs, JADE-002 and JADE-003. The company was founded upon assets licensed from Paragon Therapeutics.

Rezolute Inc., established in 2010 and headquartered in Redwood City, California, is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company's primary product candidate, RZ358, is a human monoclonal antibody currently in Phase 2b trials for treating congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. Additionally, Rezolute is advancing RZ402, a small molecule plasma kallikrein inhibitor in preclinical stages for diabetic macular edema treatment. The company aims to improve existing standards of care by applying proprietary formulation and manufacturing capabilities to known molecules.

Neurogene Inc., established in 2018 and headquartered in New York, specializes in developing genetic medicines for treating neurological disorders. The company focuses on utilizing adeno-associated virus (AAV) vectors to deliver therapeutic genes for conditions such as Charcot-Marie Tooth disease type 4J (CMT4J), Aspartylglucosaminuria (AGU), and an undisclosed Lysosomal Storage Disease (LSD). Neurogene aims to provide effective treatment options where none currently exist, aiming to improve the quality of life for patients and families affected by these rare neurological disorders.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Cellipont Bioservices is a specialized contract development and manufacturing organization (CDMO) focused on cell therapy products for biopharmaceutical companies. The company offers a range of services including the production of therapeutic proteins and antibodies, cell culture development, purification processes, troubleshooting existing manufacturing methods, and analytical development support. Additionally, Cellipont Bioservices provides cell banking and comprehensive support services to its clients, ensuring high-quality and efficient cell therapy development and production from small to large batches.

Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases.

ProMIS Neurosciences, Inc. is a development-stage biotechnology company based in Toronto, Canada, focused on developing precision therapeutic solutions for neurodegenerative diseases, primarily Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson’s disease (PD). Established in 2004, the company employs a proprietary target discovery engine that integrates thermodynamic and computational techniques to identify disease-specific epitopes on misfolded proteins. Its lead product candidates include PMN310, PMN350, and PMN330, which are monoclonal antibodies targeting toxic forms of amyloid beta oligomers and prion-like proteins associated with AD. Additionally, ProMIS is developing treatments targeting the neurotoxic tau protein in AD and proteins linked to ALS and PD. The company collaborates with BC Neuroimmunology to advance proprietary diagnostic assays and blood-based tests for Alzheimer’s disease, enhancing early detection and treatment efficacy. Formerly known as Amorfix Life Sciences Ltd., ProMIS Neurosciences has rebranded itself to reflect its focus on neurological therapeutics.

Context Therapeutics LLC is a clinical-stage biopharmaceutical company based in Philadelphia, Pennsylvania, focused on developing innovative therapies for hormone-responsive cancers. Founded in 2015, the company is dedicated to creating new medicines primarily for female cancers, including breast, ovarian, and endometrial cancer. Its lead program, Apristor (Onapristone XR), is an investigational Phase 2 drug targeting progesterone receptor positive metastatic breast and ovarian cancers. In addition to Apristor, Context is advancing CTX-030916, a potential oral antiprogestin for treating uterine fibroids and endometriosis. The company is also developing a preclinical program, CTIM-76, which is a bispecific antibody designed to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. Through its innovative pipeline, Context Therapeutics aims to address unmet medical needs in the treatment of solid tumors.

Zura Bio is a clinical-stage biotechnology company dedicated to developing innovative therapies for immune and inflammatory disorders. It focuses on advancing its pipeline of treatments through phase 2 development programs, including ZB-168 and torudokimab, which target autoimmune illnesses. ZB-168 is an anti-IL7R inhibitor designed to address disorders linked to IL7 and TSLP biological pathways, building on encouraging phase 1b data related to type 1 diabetes. Torudokimab, a human-affinity monoclonal antibody, is in phase 2 clinical development and works by neutralizing IL33. Through these initiatives, Zura Bio aims to create effective therapeutic options for patients suffering from complex immune-related conditions.

Unicycive Therapeutics provides development programs that focus on treating kidney diseases with significant unmet medical needs. It aims to open the way for a broad range of disease-modifying therapies by modifying the intracellular and extracellular concentrations of these various electrolytes and ions in Chronic Kidney Disease and Gitelman’s Syndrome and by addressing the underlying mitochondrial pathology and inflammation associated with Acute Kidney Disease. Unicycive Therapeutics was founded in 2016 and is headquartered in Los Altos, California.

Lexicon Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products to treat various human diseases. The company's portfolio includes several drug candidates in different stages of clinical trials. LX9211 is an orally-delivered small molecule being tested for neuropathic pain treatment. Sotagliflozin, another orally-delivered small molecule, is under investigation for heart failure and type 1 diabetes. Additionally, the company has developed LX4211 for type 2 diabetes, LX2931 for rheumatoid arthritis and other autoimmune diseases, and LX7101 for glaucoma treatment. Lexicon Pharmaceuticals has established collaborations with several pharmaceutical companies, including Bristol-Myers Squibb, Genentech, Organon, Takeda, Symphony Icon, Taconic Farms, and Nuevolution A/S.

Mind Medicine Inc. is a biopharmaceutical company focused on discovering, developing, and deploying psychedelic-inspired medicines and therapies aimed at addressing addiction and mental health issues. Headquartered in New York, the company is building a diverse drug development pipeline that includes innovative treatments derived from psychedelic substances such as Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative known as 18-MC. Founded in 2010 by JR Rahn, Scott Freeman, Leonard Latchman, and Stephen L. Hurst, MindMed is actively engaged in forming collaborations and conducting clinical trials to further explore the therapeutic potential of these substances in treating brain health disorders.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery. Its lead product candidate, DEXTENZA, is an ophthalmic insert that has completed Phase III clinical trials for post-surgical ocular pain, inflammation, and allergic conjunctivitis, and is also being investigated for dry eye diseases. Additionally, Ocular Therapeutix is developing several other products, including OTX-TP, an intracanalicular travoprost insert for glaucoma, and OTX-TKI, an intravitreal implant for wet age-related macular degeneration, among others. The company has established a strategic collaboration with Regeneron Pharmaceuticals to leverage its hydrogel technology in combination with Regeneron's VEGF-targeting compounds for retinal diseases. Founded in 2006 and headquartered in Bedford, Massachusetts, Ocular Therapeutix aims to address unmet needs in ophthalmology through its advanced therapeutic solutions.

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, that specializes in developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. Founded in 2018, the company aims to enhance the safety and efficacy of conditioning agents to broaden the application of curative therapies. Jasper's lead product, JSP191, is a humanized monoclonal antibody currently in clinical development, designed to act as a conditioning agent by selectively clearing hematopoietic stem cells from bone marrow in patients undergoing stem cell transplants. The company also utilizes an engineered hematopoietic stem cells platform to address the limitations of transplant grafts, thereby increasing the accessibility of both allogeneic and autologous gene-edited hematopoietic stem cell therapies for a larger patient population.

Outlook Therapeutics, Inc. is a late clinical-stage biopharmaceutical company dedicated to the development and commercialization of monoclonal antibodies for ophthalmic conditions. The company's primary focus is on its lead product candidate, ONS-5010, a proprietary ophthalmic formulation of bevacizumab, currently undergoing Phase-III clinical trials aimed at treating wet age-related macular degeneration and other retinal diseases. Outlook Therapeutics has established collaboration and licensing agreements with several international partners, including IPCA Laboratories Limited and Laboratorios Liomont, S.A. de C.V. Originally incorporated as Oncobiologics, Inc. in 2010, the company rebranded to Outlook Therapeutics, Inc. in November 2018 and is headquartered in Cranbury, New Jersey.

Ludi, Inc. is a healthcare technology company based in Nashville, Tennessee, that focuses on automating and streamlining the management of physician payments and agreements for hospitals and health systems. Founded in 2012, Ludi offers its flagship product, DocTime Log, which simplifies the process of tracking and managing physician hours and financial transactions. This mobile solution allows physicians to log their time and activities efficiently while providing hospitals with tools to audit and control their expenditures related to physician compensation. Additionally, Ludi provides consulting services aimed at enhancing relationships between healthcare organizations and their physician partners, as well as analyzing administrative structures to optimize compliance and revenue. Through its innovative solutions, Ludi addresses the complexities of physician alignment strategies, helping healthcare providers reduce administrative costs and improve operational efficiency.

Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of innovative therapies aimed at degrading disease-causing proteins. The company's lead product candidates include ARV-110, a proteolysis targeting chimera (PROTAC) currently in phase I clinical trials for metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. In addition to these, Arvinas is developing various other PROTACs aimed at degrading clinically relevant androgen receptor mutations and treatments for neurodegenerative diseases, including tauopathies. The company has established collaborations with prominent pharmaceutical firms such as Pfizer Inc., Genentech, and Bayer AG, enhancing its research capabilities and reach within the biopharmaceutical landscape. Founded in 2015, Arvinas aims to improve patient outcomes by eliminating harmful proteins from the body through its proprietary technology.

Tourmaline Bio is a clinical biotechnology company focused on developing transformative medicines aimed at improving the lives of patients suffering from immune diseases. The company is in the late stages of clinical development and is centered on its lead product candidate, TOUR006, a fully human monoclonal antibody designed to selectively target interleukin-6 (IL-6), a significant proinflammatory cytokine implicated in various autoimmune and inflammatory disorders. The IL-6 antibody class has a well-established history, with over two decades of clinical and commercial experience, having successfully treated more than a million patients with diverse autoimmune and inflammatory conditions. Through its innovative research, Tourmaline Bio seeks to address the unmet medical needs of patients affected by life-altering immune diseases.

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system disorders, particularly depressive and social anxiety disorders. The company's lead product candidate, AV-101, is an orally available treatment currently in Phase 2 development for major depressive disorder, targeting patients who have not adequately responded to standard antidepressants. Additionally, VistaGen is advancing PH94B, a neuroactive nasal spray, which is preparing for Phase III clinical trials for the acute treatment of anxiety in adults with social anxiety disorder. Another product in its pipeline, PH10, is being planned for Phase 2b development as a treatment for major depressive disorder. VistaGen has established licensing and collaboration agreements to facilitate the clinical development and commercialization of its products, including a strategic partnership for PH94B in Greater China, South Korea, and Southeast Asia. Founded in 1998, VistaGen is headquartered in South San Francisco, California.

Zura Bio is a clinical-stage biotechnology company dedicated to developing innovative therapies for immune and inflammatory disorders. It focuses on advancing its pipeline of treatments through phase 2 development programs, including ZB-168 and torudokimab, which target autoimmune illnesses. ZB-168 is an anti-IL7R inhibitor designed to address disorders linked to IL7 and TSLP biological pathways, building on encouraging phase 1b data related to type 1 diabetes. Torudokimab, a human-affinity monoclonal antibody, is in phase 2 clinical development and works by neutralizing IL33. Through these initiatives, Zura Bio aims to create effective therapeutic options for patients suffering from complex immune-related conditions.

Abivax is a clinical-stage biotechnology company based in France, dedicated to developing innovative therapeutics that leverage the body's natural immune mechanisms to treat patients with autoimmune diseases, viral infections, and cancer. The company's primary focus is on chronic inflammatory diseases, particularly inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. Abivax is currently evaluating its leading drug candidate, obefazimod, in Phase 3 clinical trials aimed at addressing moderately to severely active ulcerative colitis. Through its drug development platforms, Abivax strives to deliver novel and effective treatments to patients with significant unmet medical needs in these therapeutic areas.

Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company's pipeline includes three small molecule products. The lead program, IMU-838, is a selective immune modulator that blocks the enzyme DHODH, inhibiting the metabolism of activated immune cells and exhibiting antiviral effects. It is being developed for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, targets psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Additionally, IMU-856 aims to restore intestinal barrier function for diseases involving bowel barrier dysfunction.

iXCells Biotechnologies is a company that specializes in preclinical drug discovery solutions, primarily focusing on disease-relevant cellular models. By offering advanced technologies and services, iXCells supports the academic, biotechnology, and pharmaceutical sectors in accelerating drug discovery processes. The company aims to facilitate the development of therapeutic drugs and disease models, providing essential tools and expertise to its clients in the pursuit of innovative medical advancements.

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, that specializes in developing innovative therapies for autoimmune diseases and inflammatory disorders. Incorporated in 2018, Ventyx focuses on creating selective inhibitors targeting TYK2, a key mediator in various inflammatory conditions. The company's clinical pipeline includes VTX958, an oral allosteric TYK2 inhibitor currently in Phase 1 trials, which aims to provide a safer alternative by avoiding the toxicities linked to broader Janus kinase inhibition. Additionally, Ventyx is advancing VTX002, a Phase 2-ready S1P1 receptor modulator intended for ulcerative colitis treatment, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which plays a significant role in multiple inflammatory diseases.

Heron Therapeutics, Inc. is a biotechnology company based in San Diego, California, that focuses on developing innovative treatments to address unmet medical needs. The company utilizes its proprietary Biochronomer drug delivery technology, which enables sustained release of therapeutic agents over days to weeks with a single administration. Heron's product portfolio includes SUSTOL, an extended-release injection for preventing nausea and vomiting associated with chemotherapy, and CINVANTI, an intravenous formulation for similar indications. Additionally, the company is advancing HTX-011, a dual-acting combination of bupivacaine and meloxicam, currently in Phase III clinical trials for pain management, and HTX-034, aimed at postoperative pain relief. Founded in 1983, Heron Therapeutics was previously known as A.P. Pharma, Inc. before rebranding in 2014.

Established in 2005 with headquarters in Jersey City, New Jersey, US, Ephicacy was founded with the singular objective of being a niche provider of consultancy, functional and capability enhancement services in the area of data management, biostatistics and CDISC conversion, supporting research and clinical trials activities of leaders in the life sciences industry. Ephicacy’s presence in Bangalore, India was established in 2009 as a Center of Excellence (COE), stemming from our conviction of the locally available talent pool. Our investments in hiring and nurturing talent through well established learning and development processes have led to the creation of a competent and committed team. The COE in India is highly delivery driven with well established SOPs. Ephicacy also has an ISO 9001 : 2008 Certified quality systems. Ephicacy extended its consultancy and services operations into the European region during early 2011. Our global delivery organization comprises of a well knit team of experienced data managers, programmers, biostatisticians and domain expert based in the US, India and Europe. The India Centre of Excellence complements the capabilities of our presence in the US and Europe. Ephicacy has stepped in to address the paucity of qualified resources in these functional areas and is able to rapidly fulfill the needs of customers using flexible and bespoke business engagement models. Our highly qualified leadership team handpicks from our pool of qualified professionals to ensure customer projects are well resourced. Today, Ephicacy has proven to be pioneer and continues to be a forerunner in providing ACCURATE, RELIABLE and ON TIME solutions for the life sciences industry.

JPA Health is a comprehensive health communication agency that specializes in public relations, marketing, and advocacy. The company offers a range of services, including earned media, patient advocacy relations, public affairs, and stakeholder engagement. In addition to these core services, JPA Health also provides digital and creative solutions such as design, social media marketing, video production, and animation. By combining strategic insights with creative execution, JPA Health assists clients in developing health campaigns that aim to drive change and achieve measurable outcomes.

Cellipont Bioservices is a specialized contract development and manufacturing organization (CDMO) focused on cell therapy products for biopharmaceutical companies. The company offers a range of services including the production of therapeutic proteins and antibodies, cell culture development, purification processes, troubleshooting existing manufacturing methods, and analytical development support. Additionally, Cellipont Bioservices provides cell banking and comprehensive support services to its clients, ensuring high-quality and efficient cell therapy development and production from small to large batches.

Velentium is a designer and manufacturer of therapeutic and diagnostic medical devices, catering to clients of various sizes, from startups to established Fortune 500 companies. The company specializes in cybersecurity, device development, test systems, and medical device manufacturing. Velentium offers expertise in software, usability, cybersecurity, as well as electrical and mechanical development for medical equipment. Through these services, the company helps clients transform their intellectual property into safe and secure products that aim to improve lives. Customer inquiries are addressed through multiple channels, including phone, email, and online applications.

BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create highly selective and effective drugs. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate targeting soft tissue and bone sarcomas, non-small cell lung cancer, and other tumor types. Additionally, BioAtla is developing BA3021, aimed at non-small cell lung cancer and melanoma, as well as BA3071, which targets multiple cancers, including renal cell carcinoma and hepatocellular carcinoma. The company holds over 150 issued patents and applications, emphasizing its commitment to improving drug selectivity and safety while expanding the range of treatable cancers.

Magenta Therapeutics, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on advancing stem cell transplantation and related therapies. Founded in 2015, the company aims to enhance the patient experience in transplant medicine by developing innovative treatments that make stem cell transplants safer and more accessible. Its pipeline includes several key candidates, such as C100, C200, and C300 targeted antibody-drug conjugates designed for transplant conditioning; MGTA-145, a stem cell mobilization product; and MGTA-456, an allogeneic stem cell therapy. Additionally, Magenta is exploring E478, a small molecule aimed at expanding gene-modified stem cells, and G100, an antibody-drug conjugate to mitigate acute graft-versus-host disease. The company has established research collaborations with other biotechnology firms to further investigate the potential of its therapies in treating blood cancers, genetic disorders, and autoimmune diseases, ultimately striving to transform stem cell transplantation from a last-resort option into a more viable and effective treatment for patients.

Silence Therapeutics plc is a biotechnology company based in London, specializing in the discovery and development of innovative RNA therapeutics. The company focuses on utilizing short interfering RNA (siRNA) technology to modulate gene expression and address various medical conditions, including hematology, cardiovascular diseases, and rare metabolic disorders. Its pipeline includes several product candidates, such as SLN124, aimed at treating iron overload disorders by silencing the TMPRSS6 gene, and SLN360, which targets the LPA gene to reduce the risk of cardiovascular diseases. Silence Therapeutics has established strategic collaborations with major organizations, including AstraZeneca, to advance the development of siRNA therapeutics across multiple disease areas. The company leverages its proprietary genetic toolkit and delivery systems to optimize therapeutic outcomes, harnessing the body's natural biological mechanisms for effective treatment.

Bionova Scientific, Inc. is a biologics contract development and manufacturing organization (CDMO) based in Fremont, California. Founded by a team of biopharmaceutical specialists in 2014, the company specializes in providing comprehensive services for biologics development and manufacturing. Bionova offers expertise in cell line development for new biological entities and biosimilars, as well as early-stage research material generation and process development. The company focuses on protein production from mammalian cell cultures, optimizing expression systems, adapting hosts, selecting media, and developing cell culture processes for scale-up. Bionova supports the bioproduction of various biomolecules, including glycoproteins, monoclonal antibodies (Mabs), Fab fragments, enzymes, Fc-fusions, and bi-specifics. Through its contract manufacturing services, Bionova Scientific aims to facilitate and expedite the development of biologic therapies for its clients.

Axiom Real-Time Metrics Inc. specializes in developing eClinical software tailored for small to medium-sized life sciences organizations, including biotechnology and pharmaceutical companies. Founded in 2001 and headquartered in Toronto, Canada, the company offers a comprehensive suite of solutions that encompasses electronic data capture, data management, clinical trial management systems, randomization services, and electronic patient-reported outcomes. Axiom’s software is designed to facilitate the operational and data management needs of clients conducting clinical trials, allowing them to streamline their research processes effectively. In addition to its software offerings, Axiom provides services such as biostatistics, pharmacovigilance, and training, ensuring that clients receive comprehensive support throughout their clinical studies.

Nebula Genomics is a biotechnology company founded in 2016 and based in San Francisco, California. It specializes in human genome sequencing and the creation of a marketplace for genomic and health data aimed at consumers, researchers, and the medical community. The company's mission is to facilitate genomic sequencing and enhance personalized medicine by aggregating a substantial repository of genetic information. Utilizing blockchain technology, Nebula Genomics ensures that consumers retain control over their data and receive compensation for its use. The marketplace enables researchers to analyze rich genetic datasets, which can accelerate drug development and improve the efficiency of clinical trials. Founded by prominent genomics researcher George Church and his associates, Nebula Genomics offers advanced DNA sequencing technology that allows clients to explore all genes and genetic variants in the genome, thereby providing comprehensive insights into individual health.

Clinical Supplies Management (CSM) specializes in addressing the intricate supply challenges faced by biotech and pharmaceutical companies during clinical trials. The company offers comprehensive clinical trial and biological sample management services, which include packaging, labeling, storage, distribution, and consulting. By utilizing a combination of traditional and innovative approaches, CSM provides customized solutions that enable clients to efficiently manage drug supplies and ancillary materials, even in the face of time constraints and mid-study changes. Their extensive network and proprietary ERP systems facilitate the seamless execution of clinical trials, helping clients in the pharmaceutical, medical testing, biotechnology, and healthcare sectors to conduct efficient and effective studies while minimizing waste and costs.

Aurinia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company headquartered in Victoria, Canada, focused on developing and commercializing therapies for serious diseases with significant unmet medical needs. The company is primarily engaged in the development of voclosporin, an investigational drug aimed at treating lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia's efforts are concentrated on targeted patient populations in the United States and China, where it seeks to provide innovative solutions for conditions that currently lack effective treatments.

Apyx Medical Corp is a medical device company focused on energy technology, dedicated to developing, manufacturing, and marketing a variety of surgical and cosmetic products. The company is known for its innovative Renuvion cosmetic technology, which enables plastic and cosmetic surgeons to apply controlled heat to tissues, achieving desired aesthetic results with minimal invasiveness. Apyx Medical's flagship J-Plasma system utilizes a patented helium ionization process to generate a stable, focused beam of plasma, allowing for precise cutting, coagulation, and ablation of soft tissue while minimizing unintended damage to surrounding areas. Apyx Medical’s products are utilized in a range of settings, including doctor's offices, surgery centers, and hospitals, highlighting the company's commitment to enhancing surgical outcomes through advanced medical technologies.

HRAA interprets data to ensure that healthcare is efficient and effective for everyone by pulling medical data together to create a predictive window to understand cost and revenues looking back and going forward. Founded in 2001 and based out of Plantation, FL, HRAA combines years of industry expertise with best-in-breed technology to create market leading business intelligence products and consulting services to ensure hospitals are reimbursed for every pill they prescribe, every procedure they perform and every test they administer. HRAA both trains and supplies the high tech workforce to hospitals to generate the predictive data used by the whole healthcare system and offers a full suite of solutions needed to keep up with the ever-changing healthcare industry including data analytics software, business intelligence technology, medical coding, auditing, education, revenue cycle consulting, and ICD-10 transition solutions.

Ocera Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative treatments for patients suffering from acute and chronic liver diseases. The company's primary focus is on its lead product, OCR-002, an ammonia scavenger designed to address hyperammonemia through both intravenous and oral formulations. Recently, Ocera completed a Phase 2b clinical trial, known as STOP-HE, which assessed the safety and efficacy of OCR-002 in alleviating neurocognitive symptoms associated with acute hepatic encephalopathy in hospitalized patients with elevated ammonia levels. Ocera is currently preparing for a meeting with the FDA to discuss the intravenous program and potential future development pathways for its therapeutics.

iVantage Health Analytics is a subsidiary of The Chartis Group, headquartered in Portland, Maine with additional offices across the U.S. Established in 2006, the company specializes in healthcare analytics and business intelligence solutions. iVantage offers a range of services including Hospital Strength INDEX, VantagePoints platform, iBenchmarks scorecard, INCONTROL Contract Optimizer, EnvisionHIT GIS application, iVantage Market Intelligence, iVantage Performance Manager, market assessment, and mergers & acquisitions services. These tools help hospitals evaluate performance, optimize reimbursements, improve clinical outcomes, and make data-driven strategic decisions.

Connecture, Inc. is a web-based platform that specializes in consumer shopping, enrollment, and retention for health insurance distribution in the United States, focusing primarily on the Medicare insurance sector. Founded in 1999 and headquartered in Milwaukee, Wisconsin, the company offers personalized solutions that help users identify suitable health insurance plans based on their individual preferences, health conditions, preferred providers, medications, and anticipated out-of-pocket costs. Connecture serves a diverse clientele, including payers, brokers, government agencies, and online insurance marketplace operators. The company has refined its focus to exclusively cater to the Medicare market, providing tools such as the PlanCompare and DrugCompare product suites through software-as-a-service installations, along with integration, managed hosting, and customer support services. In 2019, Connecture was acquired by Harris Computer Systems, further solidifying its position in the health insurance technology landscape.

Aris Radiology provides a range of professional radiology services to healthcare institutions, including hospitals and surgery centers. The company is Joint Commission certified and collaborates with local medical facilities and radiology groups to deliver a comprehensive hybrid solution. Aris offers high-quality radiologists and ensures 24/7 subspecialty coverage and operational support, which enhances the quality of patient care while maintaining cost-effectiveness. Additionally, the company supports its clients with services such as patient billing, radiologist recruitment, and operational business development. This combination of expertise and service helps improve diagnostic accuracy and patient safety across the healthcare system.

WaferGen Bio-systems, Inc. is an emerging genomic analysis company in the early stage of commercialization. The company offers the transformative SmartChip Real-Time PCR System—a next-generation Real-Time PCR System for profiling and validation of gene expression patterns (biomarkers) on a single platform. The SmartChip System provides a range of high-throughput capabilities including microRNA and mRNA gene expression profiling and single nucleotide polymorphism (SNP) genotyping.

Biodel Inc. is a development-stage biopharmaceutical company based in Danbury, Connecticut, focused on creating and commercializing treatments for diabetes. The company employs its proprietary formulation technologies to enhance existing drugs, with its lead product candidate being Linjeta, a rapid-acting mealtime insulin designed for patients with Type I and Type II diabetes. In addition to Linjeta, Biodel is working on earlier-stage product candidates, including advanced rapid-acting mealtime insulins, a sublingual tablet formulation of insulin known as VIAtab, a range of basal insulins, and a glucagon formulation. Through its innovative approach, Biodel aims to improve the management of endocrine disorders, particularly diabetes.

American Surgical Professionals specializes in providing surgical assistant services to hospitals, clinics, surgeons, and patients. The company offers customized solutions for perioperative staffing needs, which include supplying skilled surgical assistants on an outsourced or contractual basis. By focusing on improving surgical care, American Surgical Professionals manages staff recruitment, scheduling, and training, thereby enabling healthcare providers to enhance patient outcomes and reduce operational costs.

Cytovance Biologics, Inc. is a biopharmaceutical contract manufacturing organization based in Oklahoma City, specializing in the production of therapeutic proteins and antibodies through mammalian cell culture and microbial fermentation. Founded in 2003, the company offers a comprehensive range of services including cell line selection, process development, purification, fill/finish operations, and cGMP manufacturing. Cytovance also provides analytical development, quality assurance, and regulatory support services to ensure compliance with industry standards. Its state-of-the-art facilities are FDA inspected, enabling the company to cater to biopharmaceutical clients across the United States. As a subsidiary of Hepalink USA Inc., Cytovance is committed to delivering innovative manufacturing solutions and support for the development and commercialization of large molecule active pharmaceutical ingredients.

Solta Medical, Inc. is a medical device company specializing in energy-based systems for aesthetic applications. Founded in 1995 and headquartered in Hayward, California, the company designs, develops, and manufactures a range of products for skin rejuvenation and body contouring. Notable offerings include the Thermage NXT system, which provides non-invasive skin tightening and cellulite enhancement, as well as the Fraxel re:fine, re:store, and re:pair systems, which address various skin conditions such as fine lines, pigmentation, acne scars, and deeper wrinkles. These systems comprise handpieces, a user-friendly console, an energy source, and disposable treatment tips. Solta Medical serves a diverse clientele, including dermatologists, plastic surgeons, and gynecologists, and distributes its products through a direct sales force and a network of distributors both in the United States and internationally. The company was previously known as Thermage, Inc. before rebranding to Solta Medical in January 2009.

BioSante Pharmaceuticals, Inc. (BioSante) is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. The Company's products for female sexual health, menopause, contraception and male hypogonadism include LibiGel, a once daily transdermal testosterone gel in Phase III clinical development under a special protocol assessment (SPA) for the treatment of female sexual dysfunction (FSD); Elestrin, a once daily transdermal estradiol (estrogen) gel indicated for the treatment of moderate-to-severe vasomotor symptoms; The Pill-Plus (triple component contraceptive), a once daily use of various combinations of estrogens, progestogens and androgens in development for the treatment of female sexual dysfunction (FSD) in women using oral or transdermal contraceptives, and Bio-T-Gel, a once daily transdermal testosterone gel in development for the treatment of hypogonadism, or testosterone deficiency, in men.

Solta Medical, Inc. is a medical device company specializing in energy-based systems for aesthetic applications. Founded in 1995 and headquartered in Hayward, California, the company designs, develops, and manufactures a range of products for skin rejuvenation and body contouring. Notable offerings include the Thermage NXT system, which provides non-invasive skin tightening and cellulite enhancement, as well as the Fraxel re:fine, re:store, and re:pair systems, which address various skin conditions such as fine lines, pigmentation, acne scars, and deeper wrinkles. These systems comprise handpieces, a user-friendly console, an energy source, and disposable treatment tips. Solta Medical serves a diverse clientele, including dermatologists, plastic surgeons, and gynecologists, and distributes its products through a direct sales force and a network of distributors both in the United States and internationally. The company was previously known as Thermage, Inc. before rebranding to Solta Medical in January 2009.

Inhibitex is a biotechnology company that specializes in the development of antibody-based products aimed at preventing and treating bacterial and fungal infections. The company is particularly focused on creating small molecule antiviral compounds, with specific attention to therapies for shingles, also known as herpes zoster, and chronic hepatitis C infections. Through its innovative approach, Inhibitex seeks to address significant medical needs in the realm of infectious diseases.

Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.

APT Pharmaceuticals is a drug development company focused on repurposing well-characterized drugs for under-served populations. APT’s initial focus is on the pulmonary delivery of treatments for serious lung diseases.

Biotronic NeuroNetwork specializes in providing neurophysiological intraoperative monitoring services to surgeons and healthcare facilities throughout the United States. The company focuses on enhancing patient safety during surgeries that pose risks to neural structures by delivering real-time monitoring and critical data analysis. With a commitment to quality care, Biotronic partners with over 650 hospitals and monitors more than 45,000 surgeries each year. Utilizing proprietary software and a secure virtual private network, Biotronic ensures reliable and efficient service, enabling surgeons to respond promptly to potential complications. The company's expertise and dedication to clinical research and education further support its mission to improve surgical outcomes while maintaining cost-effective partnerships.

As of August 20, 2008, SGX Pharmaceuticals, Inc. was acquired by Eli Lilly & Co. SGX Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of therapeutics for addressing unmet medical needs in oncology. The company's product pipeline includes drug candidates from its FAST drug discovery platform, which uses X-ray crystallography and complementary biophysical and biochemical methods, combined with medicinal and computational chemistry. Its drug development programs target the c-MET receptor tyrosine kinase (MET), an enzyme implicated in an array of cancers; and the BCR-ABL tyrosine kinase enzyme for the treatment of chronic myelogenous leukemia (CML), a bone marrow cancer. Under the MET development program, the company develops SGX523, which is in Phase I clinical development studies for solid tumor indications; and SGX126, a preclinical development product for solid tumors indications. Under the BCR-ABL Development Program, SGX Pharmaceuticals develops SGX393, an oral therapy for the second-line treatment of CML, which is in preclinical development studies. Its drug discovery technologies are also applied to a portfolio of oncology targets, including JAK2, a non-receptor tyrosine kinase involved in cytokine-induced signaling and growth regulation, survival, and differentiation of cells; RAS, a protein that regulates cell growth; and three other tyrosine kinases. The company has a license and collaboration agreement with Novartis Institutes for Biomedical Research, Inc., Cystic Fibrosis Foundation Therapeutics, Inc., National Institutes of Health, and Eli Lilly & Company. SGX Pharmaceuticals, formerly known as Structural GenomiX, Inc., was founded in 1998 and is headquartered in San Diego, California.

APT Pharmaceuticals is a drug development company focused on repurposing well-characterized drugs for under-served populations. APT’s initial focus is on the pulmonary delivery of treatments for serious lung diseases.

Caprion Proteomics, Inc. is a clinical research organization based in Montreal, Canada, specializing in proteomics and immune monitoring services for the pharmaceutical and biotechnology sectors. The company provides two primary platforms: ImmuneCarta, which utilizes multiparametric flow cytometry for in-depth analyses of immune responses, and ProteoCarta, which employs gel-free and label-free mass spectrometry to compare protein levels across biological samples for biomarker discovery. Caprion offers a diverse range of services, including cell sorting, functional profiling, biomarker discovery, and various assays, addressing multiple disease areas such as autoimmune, cardiovascular, metabolic, neurology, and infectious diseases. Established in 2000, Caprion is dedicated to advancing precision medicine in drug development through strategic partnerships, including one with Viroclinics-DDL. The company rebranded from Caprion Proteomics GP to its current name in July 2007 and operates as a subsidiary of HistoGeneX NV.

Panacos Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of small-molecule oral drugs aimed at treating human immunodeficiency virus (HIV) and other viral diseases. Established in 1999 and based in Watertown, Massachusetts, the company utilizes innovative technologies to target specific stages in the viral life cycle, such as virus maturation and fusion. Its product pipeline includes advanced programs centered on HIV maturation inhibition, representing the company's commitment to developing next-generation anti-infective therapies.

Forbes Medi-Tech Inc. is a life sciences company focused on evidence-based nutritional solutions. A leader in nutraceutical technology, Forbes is a provider of value-added products and cholesterol-lowering ingredients for use in functional foods and dietary supplements. Forbes successfully developed and commercialized its Reducol™ plant sterol blend, which has undergone clinical trials in various matrices and has been shown to lower “LDL” cholesterol levels safely and naturally. Building upon established partnerships with leading retailers and manufacturers across the globe, Forbes helps its customers to develop private label and branded products.